(NASDAQ: FENC) Fennec Pharmaceuticals's forecast annual revenue growth rate of 50.72% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 118.19%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.42%.
Fennec Pharmaceuticals's revenue in 2026 is $38,790,000.On average, 8 Wall Street analysts forecast FENC's revenue for 2026 to be $2,206,749,324, with the lowest FENC revenue forecast at $1,668,930,619, and the highest FENC revenue forecast at $2,567,516,357. On average, 7 Wall Street analysts forecast FENC's revenue for 2027 to be $2,759,807,350, with the lowest FENC revenue forecast at $2,259,299,677, and the highest FENC revenue forecast at $3,383,298,034.
In 2028, FENC is forecast to generate $3,855,660,761 in revenue, with the lowest revenue forecast at $3,277,859,925 and the highest revenue forecast at $4,631,404,073.